Marina Biotech, Inc. (Formerly Known as MDRNA, Inc.) to Report Fourth Quarter and Year-End 2010 Results on March 23, 2011 at 4:30 p.m. Eastern Time

BOTHELL, WA--(Marketwire - March 16, 2011) - Marina Biotech, Inc. (NASDAQ: MRNA), a leading RNAi-based drug discovery and development company, today announced that it will host a conference call with investors and security analysts on Wednesday, March 23, 2011, at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to provide a business update and discuss financial results for the fourth quarter and fiscal year ended December 31, 2010.

To participate in the live conference call, U.S. residents should dial 866-761-0749 and international callers should dial 617-614-2707. The participant code for the live conference call is 82083850. To access the 24-hour telephone replay, U.S. residents should dial 888-286-8010 and international callers should dial 617-801-6888. The participant code for the replay is 74922683.

Alternatively, to access the live audio webcast for this conference call, please go to the Event Calendar pages of the Investors section of Marina Biotech’s website at http://www.marinabio.com approximately 15 minutes prior to the conference call in order to register, and download any necessary software. A replay of the webcast will be available for 30 days following the event.

About Marina Biotech, Inc.

Marina Biotech is a biotechnology company, focused on the development and commercialization of RNA interference- (RNAi) and RNA-based therapeutics. The Marina Biotech pipeline currently includes a clinical program in Familial Adenomatous Polyposis (a precancerous syndrome) and two preclinical programs -- in hepatocellular carcinoma and bladder cancer. Marina Biotech has recently entered an exclusive agreement with Debiopharm Group for the development and commercialization of the bladder cancer program. Marina Biotech’s goal is to improve human health through the development of RNAi- and RNA-based compounds and drug delivery technologies that together provide superior therapeutic options for patients. Additional information about Marina Biotech is available at http://www.marinabio.com.